Sjogren’s Syndrome Treatment Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Sjogren’s Syndrome Treatment Market Overview – 8 Major Markets
    3.1    Sjogren’s Syndrome Treatment Market Historical Value (2017-2023) 
    3.2    Sjogren’s Syndrome Treatment Market Forecast Value (2024-2032) 
4    Sjogren’s Syndrome Treatment Overview 
    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Sjogren’s Syndrome Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Sjogren’s Syndrome Treatment Type Success Rate
6    Sjogren’s Syndrome Treatment Epidemiology Scenario and Forecast – 8 Major Markets
    6.1    8MM Epidemiology Scenario Overview (2017-2032)
    6.2    United States Sjogren’s Syndrome Treatment Epidemiology Scenario and Forecast (2017-2032)
    6.3    EU-4 and United Kingdom Sjogren’s Syndrome Treatment Epidemiology Scenario and Forecast (2017-2032)
        6.3.1    Germany Sjogren’s Syndrome Treatment Epidemiology Scenario and Forecast (2017-2032)
        6.3.2    France Sjogren’s Syndrome Treatment Epidemiology Scenario and Forecast (2017-2032)
        6.3.3    Italy Sjogren’s Syndrome Treatment Epidemiology Scenario and Forecast (2017-2032)
        6.3.4    Spain Sjogren’s Syndrome Treatment Epidemiology Scenario and Forecast (2017-2032)
        6.3.5    United Kingdom Sjogren’s Syndrome Treatment Epidemiology Scenario and Forecast (2017-2032)
    6.4    Japan Sjogren’s Syndrome Treatment Epidemiology Scenario and Forecast (2017-2032) 
    6.5    India Sjogren’s Syndrome Treatment Epidemiology Scenario and Forecast (2017-2032)
7    Sjogren’s Syndrome Treatment Market Landscape – 8 Major Markets 
    7.1    Sjogren’s Syndrome Treatment: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Sjogren’s Syndrome Treatment: Product Landscape
        7.2.1    Analysis by Drug Type
        7.2.2    Analysis by Therapy Type 
8    Sjogren’s Syndrome Treatment Challenges and Unmet Needs
    8.1    Sjogren’s Syndrome Treatment Type Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Sjogren’s Syndrome Treatment Type
10    Sjogren’s Syndrome Treatment Market Dynamics
    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Sjogren’s  Syndrome Treatment Market Segmentation (2017-2032) - 8 Major Markets 
    11.1    Sjogren’s Syndrome Treatment Market (2017-2032) by Drug Class
        11.1.1    Market Overview
        11.1.2    Antimalarial Quinolines
        11.1.3    Cholinergic Agents
        11.1.4    Corticosteroids 
        11.1.5    Others  
    11.2    Sjogren’s Syndrome Treatment Market (2017-2032) by Therapy Type
        11.2.1    Market Overview
        11.2.2    Targeted Drugs
        11.2.3    Pain Relievers
        11.2.4    Symptom Modulators
        11.2.5    Vaccines
        11.2.6    Surgery
        11.2.7    Others
    11.3    Sjogren’s Syndrome Treatment Market (2017-2032) by Route of Administration
        11.3.1    Market Overview
        11.3.2    Oral
        11.3.3    Intravenous
        11.3.4    Subcutaneous
        11.3.5    Others
    11.4    Sjogren’s Syndrome Treatment Market (2017-2032) by Distribution Channel
        11.4.1    Market Overview
        11.4.2    Hospital Pharmacy
        11.4.3    Retail Pharmacy
        11.4.4    Online Pharmacy
    11.5    Sjogren’s Syndrome Treatment Market (2017-2032) by Region
        11.5.1    Market Overview
        11.5.2    United States
        11.5.3    EU-4 and the United Kingdom
            11.5.3.1    Germany
            11.5.3.2    France
            11.5.3.3    Italy
            11.5.3.4    Spain
            11.5.3.5    United Kingdom
        11.5.4    Japan
        11.5.5    India 
12    United States Sjogren’s Syndrome Treatment Market (2017-2032)
    12.1    United States Sjogren’s Syndrome Treatment Market Historical Value (2017-2023) 
    12.2    United States Sjogren’s Syndrome Treatment Market Forecast Value (2024-2032)
    12.3    United States Sjogren’s Syndrome Treatment Market (2017-2032) by Drug Class
        12.3.1    Market Overview
        12.3.2    Antimalarial Quinolines
        12.3.3    Cholinergic Agents
        12.3.4    Corticosteroids 
        12.3.5    Others  
    12.4    United States Sjogren’s Syndrome Treatment Market (2017-2032) by Therapy Type
        12.4.1    Market Overview
        12.4.2    Targeted Drugs
        12.4.3    Pain Relievers
        12.4.4    Symptom Modulators
        12.4.5    Vaccines
        12.4.6    Surgery
        12.4.7    Others
13    EU-4 and United Kingdom Sjogren’s Syndrome Treatment Market (2017-2032)
    13.1    EU-4 and United Kingdom Sjogren’s Syndrome Treatment Market Historical Value (2017-2023) 
    13.2    EU-4 and United Kingdom Sjogren’s Syndrome Treatment Market Forecast Value (2024-2032)
    13.3    EU-4 and United Kingdom Sjogren’s Syndrome Treatment Market Overview
    13.4    EU-4 and United Kingdom Sjogren’s Syndrome Treatment Market (2017-2032) by Drug Class
        13.4.1    Market Overview
        13.4.2    Antimalarial Quinolines
        13.4.3    Cholinergic Agents
        13.4.4    Corticosteroids 
        13.4.5    Others  
    13.5    EU-4 and Sjogren’s Syndrome Treatment Market (2017-2032) by Therapy Type
        13.5.1    Market Overview
        13.5.2    Targeted Drugs
        13.5.3    Pain Relievers
        13.5.4    Symptom Modulators
        13.5.5    Vaccines
        13.5.6    Surgery
        13.5.7    Others
14    Japan Sjogren’s Syndrome Treatment Market
    14.1    Japan Sjogren’s Syndrome Treatment Market Historical Value (2017-2023) 
    14.2    Japan Sjogren’s Syndrome Treatment Market Forecast Value (2024-2032)
    14.3    Japan Sjogren’s Syndrome Treatment Market (2017-2032) by Drug Class
        14.3.1    Market Overview
        14.3.2    Antimalarial Quinolines
        14.3.3    Cholinergic Agents
        14.3.4    Corticosteroids 
        14.3.5    Others  
    14.4    Japan Sjogren’s Syndrome Treatment Market (2017-2032) by Therapy Type
        14.4.1    Market Overview
        14.4.2    Targeted Drugs
        14.4.3    Pain Relievers
        14.4.4    Symptom Modulators
        14.4.5    Vaccines
        14.4.6    Surgery
        14.4.7    Others
15    India Sjogren’s Syndrome Treatment Market
    15.1    India Sjogren’s Syndrome Treatment Market (2017-2032) Historical Value (2017-2023) 
    15.2    India Sjogren’s Syndrome Treatment Market (2017-2032) Forecast Value (2024-2032)
    15.3    India Sjogren’s Syndrome Treatment Market (2017-2032) by Drug Class
        15.3.1    Market Overview
        15.3.2    Antimalarial Quinolines
        15.3.3    Cholinergic Agents
        15.3.4    Corticosteroids 
        15.3.5    Others  
    15.4    India Sjogren’s Syndrome Treatment Market (2017-2032) by Therapy Type
        15.4.1    Market Overview
        15.4.2    Targeted Drugs
        15.4.3    Pain Relievers
        15.4.4    Symptom Modulators
        15.4.5    Vaccines
        15.4.6    Surgery
        15.4.7    Others
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    Japan PMDA 
        16.1.4    India CDSCO
        16.1.5    Others
17    Patent  Analysis
    17.1    Analysis by Drug Type of Patent
    17.2    Analysis by Publication Year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants  Analysis
    18.1    Analysis by Year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization 
19    Clinical  Trials Analysis
    19.1     Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Funding  and Investment Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Drug Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Drug Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Supplier Landscape
    22.1    Market Share by Top 5 Companies
    22.2    Denali Therapeutics
        22.2.1    Financial Analysis 
        22.2.2    Product Portfolio 
        22.2.3    Demographic Reach and Achievements 
        22.2.4    Mergers and Acquisitions 
        22.2.5    Certifications 
    22.3    Clovis Oncology
        22.3.1    Financial Analysis 
        22.3.2    Product Portfolio 
        22.3.3    Demographic Reach and Achievements 
        22.3.4    Mergers and Acquisitions 
        22.3.5    Certifications 
    22.4    Horizon Therapeutics Plc
        22.4.1    Financial Analysis 
        22.4.2    Product Portfolio 
        22.4.3    Demographic Reach and Achievements 
        22.4.4    Mergers and Acquisitions 
        22.4.5    Certifications 
    22.5    Sangamo Therapeutics
        22.5.1    Financial Analysis 
        22.5.2    Product Portfolio 
        22.5.3    Demographic Reach and Achievements 
        22.5.4    Mergers and Acquisitions 
        22.5.5    Certifications 
    22.6    AbbVie Inc.
        22.6.1    Financial Analysis 
        22.6.2    Product Portfolio 
        22.6.3    Demographic Reach and Achievements 
        22.6.4    Mergers and Acquisitions 
        22.6.5    Certifications 
    22.7    Advanz Pharma
        22.7.1    Financial Analysis 
        22.7.2    Product Portfolio 
        22.7.3    Demographic Reach and Achievements 
        22.7.4    Mergers and Acquisitions 
        22.7.5    Certifications 
    22.8    Biogen Inc.
        22.8.1    Financial Analysis 
        22.8.2    Product Portfolio 
        22.8.3    Demographic Reach and Achievements 
        22.8.4    Mergers and Acquisitions 
        22.8.5    Certifications 
    22.9    Bristol-Myers Squibb Company
        22.9.1    Financial Analysis 
        22.9.2    Product Portfolio 
        22.9.3    Demographic Reach and Achievements 
        22.9.4    Mergers and Acquisitions 
        22.9.5    Certifications 
    22.10    Daiichi Sankyo Company, Limited
        22.10.1    Financial Analysis 
        22.10.2    Product Portfolio 
        22.10.3    Demographic Reach and Achievements 
        22.10.4    Mergers and Acquisitions 
        22.10.5    Certifications
    22.11    Hikma Pharmaceuticals PlC
        22.11.1    Financial Analysis 
        22.11.2    Product Portfolio 
        22.11.3    Demographic Reach and Achievements 
        22.11.4    Mergers and Acquisitions 
        22.11.5    Certifications
    22.12    Johnson and Johnson
        22.12.1    Financial Analysis 
        22.12.2    Product Portfolio 
        22.12.3    Demographic Reach and Achievements 
        22.12.4    Mergers and Acquisitions 
        22.12.5    Certifications
23    Sjogren’s Syndrome Treatment Sjogren’s Syndrome Treatment Type - Distribution Model (Additional Insight)
    23.1    Overview 
    23.2    Potential Distributors 
    23.3    Key Parameters for Distribution Partner Assessment 
24    Key Opinion Leaders (KOL) Insights (Additional Insight)
25    Company Competitiveness Analysis (Additional Insight)
    25.1    Very Small Companies
    25.2    Small Companies
    25.3    Mid-Sized Companies
    25.4    Large Companies
    25.5    Very Large Companies
26    Payment  Methods (Additional Insight)
    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket

 *Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.